Cronos Group Inc (CRON) Stock Price Today
Aura AI Summary
Key Stats
- $1.24BMarket Cap
- 1,009,394Volume
- HealthSector
- $3.5552W High
- $2.3052W Low
- 23 DaysTypical Hold Time
- $443.61MEnterprise Value
- -Div Yield
- -Trading Activity
Track Cronos Group Inc (CRON) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Cronos Group Inc has traded between a low of $2.3 and a high of $3.55, highlighting its annual price range. Buy and sell Cronos Group Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Most Recent News
FarmQA and Planet launch AI-driven sugar beet yield forecasting using satellite and field data.
FarmQA and Planet Labs have partnered to develop AI-powered agronomic tools for enterprise agriculture, starting with a sugar beet yield estimation model. This model combines Planet's satellite imagery with FarmQA's field-verified agronomic data to p...

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.